Concentrations of Irinotecan and SN-38 in the Ascites and the Fluid Product of Cell-Free and Concentrated Ascites Reinfusion Therapy 9 Days After Administration of Irinotecan in a Patient with Gastric Cancer: A Case Report.

Keisuke Baba, Tomoki Tanie, Yasuo Matsubara, Yoshihiro Hirata, Hiroaki Ikematsu, Chiyo K Imamura, Narikazu Boku

Abstract readCase Reports

In one paragraph

Article in OncoTargets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Keisuke BabaDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Tomoki TanieDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Yasuo MatsubaraDivision of Advanced Gastroenterology and Endoscopy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Yoshihiro HirataDivision of Advanced Gastroenterology and Endoscopy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Hiroaki IkematsuDivision of Advanced Gastroenterology and Endoscopy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Chiyo K ImamuraAdvanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.

Narikazu BokuDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cell-free and concentrated ascites reinfusion therapy (CART) is frequently used to relieve the symptoms caused by massive ascites due to peritoneal metastasis of gastric cancer, especially in the later stages of its clinical course. Irinotecan (CPT-11) is recommended for third- or later-line chemotherapy according to gastric cancer treatment guidelines. However, the concentrations of anti-cancer drugs in the ascites and the product of CART are not well known, it is considered that some amounts of anti-cancer drugs contained in the product of CART may be readministered and induce severe adverse reactions. Case Presentation: A 66-year-old female with gastric cancer and massive ascites received third-line chemotherapy with CPT-11 (150 mg/m Conclusion: Concentrations of CPT-11 and SN-38 remaining in ascites and the product of CART were low in an advanced gastric cancer patient 9 days after administration of CPT-11.

Indexed as

CARTcell-free and concentrated ascites reinfusion therapyconcentrationCPT-11gastric canceririnotecanSN-38

Identifiers

PMID39588517

DOI10.2147/OTT.S486272

PMCPMC11586449

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.